Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orquest

This article was originally published in The Gray Sheet

Executive Summary

Clinical studies of firm's Ossigel bone growth factor will begin the third quarter of 2001 to support a PMA submission in early 2003. Orquest is currently completing a feasibility study in the U.S., while a 140-patient study is under way in Europe to evaluate Ossigel's performance in healing fresh fractures. The company emphasizes that it is the sole developer of the product, and that it maintains a manufacturing contract with Anika Therapeutics. "The Gray Sheet" (Jan. 22, 2001, p. 15) had suggested that Ossigel is being jointly developed
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT038331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel